
News and Insight for Decision-Makers
Editor's Pick
Inside San Francisco's new AI school: is this the future of US education?
The private Alpha School says its students can learn faster and better - but experts warn not all may benefit from an AI boom in schools
Continued here |
High-signal, zero noise. Expense Premium.
Work
Work
Work
Work
Work
Work
Work
Work
Work
Work
Work
Work
Work
Work
Work
Work
Work
Work
Work
Work
Work
Spyware maker NSO Group blocked from WhatsApp A federal judge has granted Meta-owned WhatsApp's request for a permanent injunction blocking Israeli cyberintelligence company NSO Group from targeting the messaging app's users. At the same time, the judge dramatically reduced the fine that NSO Group must pay to Meta.
Work
Work
The U.S. is the world's bribery cop. Is that about to change? The U.S. has been policing bribery all over the world for nearly half a century using a law called the Foreign Corrupt Practices Act. But now, President Trump has said that this anti-corruption law is crippling American businesses. Since taking office, his administration has reduced the number of investigators, killed some cases, and changed the rules.
Work
Work
Work
Work
Work
Work
The Tech Right Gets Its Own Phyllis Schlafly Katherine Boyle, an influential venture capitalist who is a friend of the vice president, thinks the country’s path forward involves cultural conservatism and more weapons production.
Work
Work
Work
Work
Work
Betfred says gambling tax rise in budget will force it to shut all its UK shops In its latest earnings report, Betfred said it made £500,000 in operating profit on £900,000 in revenues, following a series of writedowns on its assets in 2023. The company has yet to release its earnings report for 2024, when it was fined £3.25m by the Gambling Commission for social responsibility and anti-money-laundering failures.
Work
Work
Work
Work
Work
At ESMO, AstraZeneca, Gilead square off in triple-negative breast cancer Researchers were already going to be comparing the results of the two Phase 3 studies in the difficult-to-treat tumors, but the stakes were upped with the trials being presented back-to-back here at the European Society for Medical Oncology’s annual conference. A single discussant also analyzed the results together, parsing the outcomes for Gilead’s Trodelvy as well as for Datroway, made by AstraZeneca and its partner Daiichi Sankyo.
Work
Work
Work
Work
Work
Work
Work
Work
Work
Work
TradeBriefs Publications are read by over 100,000 Industry Executives
About Us | Advertise | Privacy PolicyUnsubscribeYou are receiving this mail because of your subscription with TradeBriefs.
Our mailing address is 3110 Thomas Ave, Dallas, TX 75204, USA
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|